Social Isolation May Worsen Breast Cancer Prospects stat : khn

This content may collect you by Lucy William

We will quote to you most important and trendy news about all kind of Cancer of the best health sites Like : "khn" and the most famous medical experts :

daily : 2016-12-14 & on time : 4:58

according to

Social Isolation May Worsen Breast Cancer Prospects

image uploaded by "khn" site
Patients with early breast cancer who are socially isolated have a higher risk of dying from their disease, a new study suggests.Women with fewer social ties — to friends, family, community and religious groups, as well as spouses or romantic partners — were 43 percent more likely to see their breast cancer return, 64 percent more likely to die from breast cancer and 69 percent more likely to die from any cause, according to a study published Monday in the journal Cancer.Although the study finds a link between social ties and health, it doesn't prove that strong social support actually prolongs life, said coauthor Wendy Chen, a breast cancer medical oncologist at Boston's Dana-Farber Cancer Institute.While researchers considered a number of explanations for the difference in women's outcomes, it's possible that something other than social support explains why some women lived longer than others.
about the details read more from here

Brock Schroeder Discusses BCI Findings in ER+ Breast Cancer

image uploaded by "onclive" site
Brock Schroeder Discusses BCI Findings in ER+ Breast CancerBrock Schroeder, PhD Published Online: Tuesday, Dec 13, 2016Brock Schroeder, PhD, senior director, Medical and Scientific Affairs at bioTheranostics, discusses findings regarding the Breast Cancer Index (BCI) in predicting patients with estrogen receptor (ER)-positive breast cancer at high risk of recurrence.In this study, researchers investigated 2 cohorts of patients who had ER-positive, early-stage disease with clinically low-risk breast cancer.Researchers sought to determine whether the BCI could stratify patients based on their risk of late recurrence.This is an important issue, Schroeder says, given the findings of the NSABP B-42 trial, which showed that only a small proportion of patients benefitted from extended endocrine therapy.